CEA has been extensively studied and used as a cancer marker (Hester et al., 2021; Moretto et al., 2021; Taheri et al., 2022), whereas PSG, especially PSG7, has been relatively poorly studied in the field of oncology, (Su et al., 2020). This evidence concerns the gene PSG2 and cancer.